Anrikefon
As of the edition of 20 October 2026, Anrikefon is a small molecule: stopped in 2026; acts on OPRK1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2026
- Kind
- Small molecule
- Registered trials
- 9, 1 stopped early
- Disease areas
- Nervous system; Pregnancy and women's health; Urinary and reproductive; Digestive system; Immune system; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| OPRK1 | Kappa-type opioid receptor | P41145 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 1 | 0 |
| Phase 2 | 3 | 0 | 3 | 0 |
| Phase 4 | 5 | 0 | 4 | 1 |
| All trials | 9 |